Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients

References

• Mayes M, Reveille J. 2004. Epidemiology, demographics, and genetics in systemic sclerosis. Philadelphia, PA, USA.: Lippincott Williams & Wilkins1–15.
   Google Scholar
• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. NEJM. 2009; 360 19: 1989–2003.
   PubMed Web of Science ®Google Scholar
• Steen V. The many faces of scleroderma. Rheum Dis Clin N Am. 2008; 34:1–15.
   PubMed Web of Science ®Google Scholar
• Hu PQ, Fertig N, Medsger TAJr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum. 2003; 48:1363–1373.
   PubMedGoogle Scholar
• Kuwana M, Kaburaki J, . Autoantibody reactive with three classes of RNA Polymerases in sera from patients with Systemic Sclerosis. J Clin Invest. 1993; 31 4: 1399–1404.
   Google Scholar
• Okano Y, Steen V, Medsger TAJr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med. 1996; 119 10: 1005–1013.
   Google Scholar
• Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TAJr. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009; 60 4: 1112–1118.
   PubMedGoogle Scholar
• Medsger TAJr. 2004. Classification, prognosis in systemic sclerosis. Philadelphia, PA, USA: Lippincott Williams & Wilkins17–28.
   Google Scholar
• Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TAJr. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum. 2003; 48:203–209.
   PubMed Web of Science ®Google Scholar
• Williams J, Lucas M, Fertig N, Medsger TAJr.. Anti-Ku antibody in patients with systemic sclerosis: Comparison of clinical features associated with anti-U1 RNP, anti-U3 RNP, and anti-PM-Scl antibodies. Arthritis Rheum. 2005; 52 Suppl: S590–S591.
   Google Scholar
• Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol. 1989; 16:328–334.
   PubMed Web of Science ®Google Scholar
• Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: Clinical, genetic and diagnostic insights. Autoimmun Rev. 2007; 6:432–437.
   PubMed Web of Science ®Google Scholar
• Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airo P, Cattaneo R, . Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus. 2008; 17:727–732.
   PubMedGoogle Scholar
• Harris ML, Rosen A. Autoimmunity in scleroderma: The origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol. 2003; 15 6: 778–784.
   Google Scholar
• Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TAJr, . Anti-U11/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosis. Arthritis Rheum. 2009; 61 7: 958–965.
   PubMedGoogle Scholar
• Mayes MD, Lacey JVJr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, . Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48 8: 2246–2255.
   PubMedGoogle Scholar
• Agarwal SK, Reveille JD. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol. 2010; 22 2: 133–138.
   Google Scholar
• Ibáñez G. Esclerosis sistémica (Escleroderma). Rev Mex Reumat. 2003; 18 2: 123–132.
   Google Scholar
• Rojas-Serrano J, Codina-Velasquez H, Medrano-Ramírez G, Simón JA, Vera-Lastra O, Vazquez-Mellado J. Menor incidencia de daño grave en órganos diana en pacientes Mexicanos con Esclerosis Sistémica con afección cutánea difusa. Rheumatol Clin. 2008; 4 1: 3–7.
   Google Scholar
• Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 23:581–590.
   PubMed Web of Science ®Google Scholar
• Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, . Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis. A twenty-year prospective study of 586 patients, with validation of proposed criteria early systemic sclerosis. Arthritis Rheum. 2008; 58:3902–3912.
   PubMed Web of Science ®Google Scholar
• Medsger TAJr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003; 21 Suppl 29: S60–S64.
   Google Scholar
• Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, . For the GENISOS Study Group. Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic and immunogenetic determinants. Semin Arthritis Reum. 2001; 30 5: 332–346.
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, . Clinical risk assessment of organ manifestations in Systemic Sclerosis: A report from the EULAR Scleroderma Trials and Research Group Database. Ann Rheum Dis. 2007; 66:754–763.
   PubMed Web of Science ®Google Scholar
• Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TAJr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007; 34:104–109.
   PubMed Web of Science ®Google Scholar
• Steen V. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005; 35:35–42.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with Systemic Sclerosis. Arthritis Rheum. 1994; 37 1: 75–83.
   PubMedGoogle Scholar
• Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TAJr. Racial differences in the distribution of Systemic Sclerosis-related serum antinuclear antibodies. Arthritis Rheum. 1994; 37 6: 902–906.
   PubMed Web of Science ®Google Scholar
• Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S, . Distribution and antigen specificity or anti-U1 RNP antibodies in patients with Systemic Sclerosis. Clin Exp Immunol. 1999; 117:383–387.
   Google Scholar
• Mahler M, Fritzler MJ. The changing landscape of the clinical value of the PM/Scl autoantibody system. Arthritis Res Ther. 2009; 11:106–107.
   Google Scholar
• Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TAJr. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 2005; 52 8: 2425–2432.
   Google Scholar
• Okano Y, Steen V, Medsger TAJr. Autoantibody reactive with RNA Polymerase III in Systemic Sclerosis. Ann Intern Med. 1996; 119 10: 1005–1013.
   Google Scholar
• Parker JC, Burlingame RW, Webb TT, Bunn CC. Anti-RNA polymerase III antibodies in patients with Systemic Sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology. 2008; 47:976–979.
   PubMedGoogle Scholar
• Rozman B, Cucnik S, Sodin-Semrl S, Czirjak L, Varju C, Distler O, . Prevalence and clinical associations of anti-Ku antibodies in patients with Systemic Sclerosis: A European EUSTAR-initiated Multi-Centre Case-Control Study. Ann Rheum Dis. 2008; 67:1282–1286.
   PubMed Web of Science ®Google Scholar
• Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, . Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 2000; 43 1: 76–84.
   Google Scholar
• Villalta D, Tozzoli R, Bizzaro N, Tonutti E, Ghirardello A, Doria A. The relevance of autoantigen source and cutoff definition in antichromatin (Nucleosome) antibody immunoassays. Ann NY Acad Sci. 2005; 1050:176–184.
   PubMedGoogle Scholar
• Putová I, Dostal C, Becvar R. Prevalence of antinucleosome antibodies by enzyme-linked immunosorbent assays in patients with Systemic Lupus Erythematosus and other autoimmune systemic diseases. Ann NY Acad Sci. 2007; 1109:275–286.
   PubMedGoogle Scholar
• Düzgün N, Sahin M, Genc Y, Tutkak H. Antinucleosome antibodies and Systemic Lupus Erythematosus. Ann NY Acad Sci. 2007; 1109:421–428.
   PubMed Web of Science ®Google Scholar
• Simón JA, Cabiedes J, Ortíz E, Alcocer-Varela J, Sánchez-Guerrero J. Anti-nucleosome antibodies in patients with Systemic Lupus Erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology. 2004; 43:220–224.
   PubMedGoogle Scholar
• Pope JE. Scleroderma overlap syndromes. Curr Opin Rheumatol. 2002; 14:704–710.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Nardi N, Brito-Zeron P, Aguilo S, gil V, Delgado G, Bove A, Font J. Atypical autoantibodies in patients with rimary Sjögren syndrome: Clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum. 2006; 35:312–321.
   PubMed Web of Science ®Google Scholar
• Alvarado-de la Barrera C, Zúñiga-Ramos J, Ruíz-Morales JA, Estañol B, Granados J, Llorente L. HLA class II genotypes in Mexican Mestizos with familial and nonfamilial multiple sclerosis. Neurology. 2000; 55 12: 1897–1900.
   Google Scholar
• Vargas-Alarcón G, Granados-Arriola J, Alarcón-Segovia D. Estudios inmunogenéticos en Escleroderma. Rev Mex Reumat. 1993; 8 2: 112–116.
   Google Scholar
• Vargas-Alarcón G, Granados J, Ibañez de Kasep J, Alcocer-Varela J, Alarcón-Segovia D. Association of HLA-DR5 (DR11) with Systemic Sclerosis (Scleroderma) in Mexican patients. Clin Exp Rheumatol. 1995; 13:11–16.
   PubMedGoogle Scholar
• Arnett FC, Gourh P, Shete S, Ahn CW, Honey RE, Agarwal SK, Tan FK, McNearney T, Fischbach M, Fritzler MJ, Mayes MD, Reveille JD. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: Analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis. 2010; 69 5: 822–827.
   PubMed Web of Science ®Google Scholar
• Simeon CP, Fonollosa V, Tolosa C, Palou E, Selva A, Solans R, Armadans L, Moreno E, Marsal S, Vilardell M. Association of HLA class II genes with systemic sclerosis in Spanish patients. J Rheumatol. 2009; 36 12: 2733–2736.
   PubMed Web of Science ®Google Scholar